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Effect of levothyroxine on cardiac function in children with 
subclinical hypothyroidism: A quasi-experimental study 
 
Abstract 
Background: Because of the importance of thyroid function and its effect on different 
organs, such as the heart, this study was aimed to evaluate the effect of levothyroxine on 
cardiac function in children with subclinical hypothyroidism. 
Methods: This quasi-experimental study was performed on children aged 4-12 years old 
with diagnosis of subclinical hypothyroidism in Amirkola Children's Hospital during 
2018-2019. Cardiac functional parameters, including ejection fraction (EF), fractional 
shortening (FS), ratio of early filling velocity to early diastolic mitral annulus velocity 
(E/E'), myocardial performance index (MPI), left ventricular end-diastolic diameter 
(LVEDD), and left ventricular end-systolic diameter (LVESD), were measured by 
echocardiography at baseline and 6 months after levothyroxine treatment. 
Results: Out of the 30 subjects, 19 (63.3%) were boys and 11 (36.7%) were girls. The 
mean age was 6.60±2.13 years old. The mean EF index was 63.13±3.01 percent before 
treatment, which increased to 69.07±4.50 percent after treatment (p<0.001). Also, the 
mean FS was 31.83±1.62 percent before treatment, which improved to 35.10±1.13 percent 
after treatment (p<0.001). The mean MPI was 0.28±0.02 before treatment, which increased 
to 0.33±0.03 after treatment (p<0.001). On the other hand, no significant difference was 
found in the mean E/E' before and after treatment. The mean LVEDD decreased from 
3.47±0.46 cm before treatment to 3.05±0.40 cm after treatment (p<0.001), whereas 
LVESD non-significantly decreased after treatment versus before treatment. 
Conclusion: The results showed that treatment with levothyroxine may improve cardiac 
functional parameters in children with subclinical hypothyroidism. 
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Subclinical hypothyroidism is a branch of hypothyroidism which is characterized by 
increased thyroid stimulating hormone (TSH) and normal thyroxine (T4) (1). The 
prevalence of subclinical hyperthyroidism in pediatrics is about 2% and its incidence is 
more in girls than in boys (2, 3). Some of the complications of subclinical hypothyroidism 
include changing lipid profiles, increase blood coagulation and changing cardiac function 
especially left ventricle (4, 5). Cardiovascular system is sensitive to thyroid hormone 
activity. Although a wide spectrum of cardiac disorders has been identified in patients with 
thyroid dysfunctions, cardiac involvement in patients with subclinical hypothyroidism has 
been discussed over the recent two-three decades. Effects of subclinical hypothyroidism on 
cardiovascular system are directly related to severity of thyroid hormone deficiency. 
Subclinical hypothyroidism causes increase in systemic vascular resistance, diastolic 
dysfunction and decrease in preload of heart (6, 7). It can also lead to heart failure and 
coronary artery lesions (8). 
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There is conflicting evidence on the effect of subclinical 
hypothyroidism on decrease in systolic functions. Some 
papers stated that subclinical hypothyroidism can decrease 
systolic function (9, 10), but some others are not compatible 
with this result (11, 12). Thyroid hormones can affect 
cardiovascular system through transcriptional regulation and 
regulatory proteins (13, 14). In addition, hypothyroidism can 
contribute in chronic inflammations and tissue changes (such 
as dehydration and collagen alternation), and also 
hemodynamic changes by influence on arterial smooth 
muscle (15, 16). Cardiovascular complications of subclinical 
hypothyroidism can be seen in children and adults. 
Some articles stated that treatment with levothyroxine 
was associated with positive effects on cardiac function in 
adults with subclinical hypothyroidism suffering from 
cardiovascular complications (17-20). However, number of 
studies assessing the effects of levothyroxine on cardiac 
complications in pediatric population is limited. Considering 
the importance of proper thyroid function and its effect on 
different organs, such as heart which has a vital role in 
correct function of various organs and in improving the 
growth and development of children, it would be clinically 
helpful to find a therapeutic option in pediatric patients with 
subclinical hypothyroidism to treat and prevent them from 
potential cardiac complications in the future. The purpose of 
the present study was to evaluate the effects of treatment 
with levothyroxine on cardiac function in the pediatric 
patients with subclinical hypothyroidism. 
 
 
Methods 
This open-label quasi-experimental study was performed 
in 2018-2019 on children aged 4-12 years old, who were 
referred to the endocrinology clinic of the Amirkola 
Children's Hospital with the diagnosis of subclinical 
hypothyroidism, or the children who came for growth 
evaluation and were diagnosed as subclinical 
hypothyroidism by laboratory tests (elevated TSH and 
normal T4). Diagnosis of subclinical hypothyroidism was 
done by pediatric endocrinologist. 
The exclusion criteria were as follows: 
1. Being overweight (body mass index [BMI, kg/m2] between 
85th and 95th percentile), obesity (BMI higher than 95
th
 
percentile), or underweight (BMI lower than 5th percentile) (21). 
2. Hypertension (higher than 95th percentile for age, sex and 
height) (21) 
3. Previous use of levothyroxine, anticonvulsants 
4. Precocious puberty (22, 23) 
5. Pathologic bradycardia or tachycardia (24) 
6. Congenital or acquired heart disease and under medical 
treatment 
7. Liver or kidney disease 
8. Hyperlipidemia 
9. Diabetes 
10. Infectious diseases 
All subjects were initially examined for thyroid, maturity 
stage, hypertension and pulse rate and their height and 
weight were recorded. The examination was conducted by 
the pediatric resident under supervision of the pediatric 
endocrinologist. Height and weight of the patients were 
evaluated and recorded by BALAS equipment (Nikan 
Andishan Nozhan Co, Tehran, Iran) with measurement error 
of 0.2 grams and then BMI was calculated using formula of 
weight (kilograms) divided by height (square meters). Blood 
pressure was assessed in the prone and rest position using the 
sphygmomanometer Heine (made in Germany). To conduct 
thyroid tests, 2 cc blood was collected after 8-10 hours 
fasting and then levels of TSH and T4 were measured using 
enzyme-linked immunosorbent assay (ELISA) kits (Pishtaz 
Teb, Tehran, Iran) in the laboratory of Amirkola Children's 
Hospital. Normal range for THS was 0.5-5.5 mIu/l and for 
T4 was 5.5-12.8 µg/dl (prepubertal children: 3-10 years old) 
or 4.2-13µg/dl (pubertal children >10 years old) (24). 
After approving subclinical hypothyroidism, the subjects 
underwent echocardiography for the evaluation of cardiac 
function, using a Medison Accuvix V10 ultrasound 
equipment (Samsung Medison, Seoul, South Korea) by the 
pediatric cardiologist. Study outcomes and parameters of 
cardiac function assessed were as follows: 
 Left ventricular end-systolic diameter (LVESD): 
Normal value depends on age, including 1.9±0.3 (1-5 years 
old), 2.4±0.3 (6-9 years old), 2.7±0.3 (10-13 years old) (25). 
 Left ventricular end-diastolic diameter (LVEDD): 
Normal value depends on age, including 3.1±0.4 (1-5 years 
old), 3.9±0.4 (6-9 years old), 4.3±0.4 (10-13 years old) (25). 
 Fractional shortening: It is defined as percentage of 
changes of left ventricular dimensions between end-diastole 
and end-systole (25). It is measured using the following 
formula and the normal range is between 28% and 38%: 
(LVEDD-LVESD)/LVEDD×100. 
 Ejection fraction (EF): It is a volume parameter showing 
changes of left ventricular volume between end-diastole and 
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end-systole (25). It is measured using the following formula 
and the normal range is between 54% and 75%: (left 
ventricular end-diastolic volume [LVEDD]- left ventricular 
end-systolic volume [LVESD])/LVEDD×100. 
 Ratio of early filling velocity to early diastolic mitral 
annulus velocity (E/E'): It is a strong predictor of post-acute 
myocardial infarction complications, hypertensive cardiac 
diseases, severe secondary mitral insufficiency, end stage 
renal disease, atrial fibrillation and cardiomyopathies (26). 
Normal value depends on age, including 8.1±1.8 (1-5 years 
old), 7.7±1.6 (6-9 years old), 6.6±1.4 (10-13 years old). 
 Myocardial performance index (MPI) or Tei index: It 
includes both systolic and diastolic time intervals to assess 
the global cardiac dysfunction (26). It is measured using the 
following formula and the normal value is 0.35±0.03 for left 
ventricle: (Isovolumic relaxation time+Isovolumic 
contraction time)/ Ejection time. 
Patients with abnormal range of the mentioned 
parameters and clinical symptoms of heart failure, such as 
fatigue, anorexia, cough, dyspnea, sweating, abdominal pain, 
edema, hepatomegaly, orthopnea, rale in auscultation, and so 
on, were excluded from the study. The sample size was 
estimated as 30 patients per group by a power of 80%, effect 
size of 0.7 and confidence level of 95%. Treatment was 
started with tablet levothyroxine 0.1 mg (Iran Hormone 
Pharmaceutical Co, Tehran, Iran) with dose of 4 µ/kg/day 
before breakfast. Echocardiography was performed before 
and 6 months after starting levothyroxine treatment by the 
same cardiologist. The cardiologist was unaware of the 
intervention groups. Thyroid function tests (TSH and T4) 
were reassess 1.5 months after starting treatment and then 
every 2 months.  
The obtained data were analyzed using SPSS statistical 
software. The descriptive analysis was used for the 
determination of the frequency, percentages, mean and 
standard deviation. Normality of the data was tested using 
the Kolmogorov-Smirnov test. Paired t-test and Wilcoxon 
signed rank were used to compare the parametric and non-
parametric data, respectively, before and after the treatment. 
We utilized the exact method of bootstrap to calculate the p-
value. A p-value of <0.05 was considered to be significant in 
all tests. The informed written consent was signed by all 
subjects' parents at the beginning of the study. The patients’ 
information was kept confidential. This study was approved 
by the Ethics Research Committee of Babol University of 
Medical Sciences (code: IR.MUBABOL.HRI.REC.1397.153). 
This trial was registered in the Iranian Registry of Clinical 
Trials with the number IRCT20180228038900N3. 
 
 
Results 
Out of 30 subjects, 19 (63.3%) were boys and the rest 
were girls. The mean serum level of T4 was 8.42±2.01 µg/dl 
before treatment and 8.38±2.22 µg/dl at six months of 
treatment (p=0.86). The mean serum level of TSH was 
8.77±1.47 mIu/l before treatment and 3.36±2.17 mIu/l at six 
months of treatment (<0.001). Figure 1 indicates the 
CONSORT flow diagram. Table 1 also shows the baseline 
information of the patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. CONSORT flow diagram 
 
Table 1. Baseline information of children with subclinical 
hypothyroidism 
Variable Results 
Sex (boy/girl), number 19/11 
Age, mean±SD, years old 6.60±2.13 
Body Mass Index, mean±SD, kg/m
2
 16.55±4.00 
T4, mean±SD, µg/dl 8.42±2.01 
TSH, mean±SD, mIu/l 8.77±1.47 
Table 2 shows comparison of cardiac functional 
parameters before and six months after treatment with 
levothyroxine in the patients. The mean EF index was 
63.13±3.01 before treatment, which increased to 69.07±4.50 
after treatment (p<0.001). Also, the mean FS was 
31.83±1.62 before treatment, which improved to 35.10±1.13 
after treatment (p<0.001). The mean MPI was 0.28±0.02 
before treatment, which increased to 0.33±0.03 at six months 
of treatment (p<0.001). On the other hand, no significant 
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difference was found in the mean E/E' before and after 
treatment. The mean LVEDD decreased from 3.47±0.46 
before treatment to 3.05±0.40 after treatment (p<0.001), 
whereas LVESD did not significantly decrease after 
treatment compared with before treatment. Table 3 indicates 
comparison of cardiac functional parameters before and six 
months after treatment with levothyroxine by sex. In both 
boys and girls, EF, FS and MPI significantly increased after 
treatment compared with before treatment. LVEDD also 
significantly decreased after treatment compared with before 
treatment in both sexes. E/E' parameter increased in boys, 
but did not significantly increase in girls. 
Table 2.Cardiac functional parameters before and six months after treatment with levothyroxine, in children with 
subclinical hypothyroidism 
Variables Before treatment  
(mean±SD) 
Six months of treatment  
(mean±SD) 
P-value 
Systolic parameters    
EF
a
 (%) 63.13±3.01 69.07±4.50 <0.001 
FS
b
 (%) 31.83±1.62 35.10±1.13 <0.001 
Diastolic parameter    
E/E'
c 
6.31±0.71 6.49±0.74 0.07 
Global ventricular performance    
MPI
d 
0.28±0.02 0.33±0.03 <0.001 
Cardiac morphological parameters    
LVEDD
e
 (cm) 3.47±0.46 3.05±0.40 <0.001 
LVESD
f
 (cm) 2.08±0.36 2.02±0.44 0.64 
a Ejection fraction; b Fractional shortening; c Ratio of early filling velocity to early diastolic mitral annulus velocity; d myocardial performance index; e left 
ventricular end-diastolic diameter; f left ventricular end-systolic diameter 
Table 3. Cardiac functional parameters before and six months after treatment with levothyroxine, in children with 
subclinical hypothyroidism by sex 
Sex Variables Before treatment  
(mean±SD) 
Six months of treatment  
(mean±SD) 
P-value 
B
o
y
s 
Systolic parameters    
EF
a
 (%) 62.95±3.29 69.63±4.17 <0.001 
FS
b
 (%) 31.42±1.50 35.05±2.19 <0.001 
Diastolic parameter    
E/E'
c 
6.34±0.63 6.60±0.72 0.010 
Global ventricular performance    
MPI
d 
0.28±0.03 0.33±0.02 <0.001 
Cardiac morphological parameters    
LVEDD
e
 (cm) 3.49±0.48 3.01±0.45 <0.001 
LVESD
f
 (cm) 2.09±0.30 2.00±0.48 0.990 
G
ir
ls
 
Systolic parameters    
EF (%) 63.45±2.52 68.09±5.06 0.040 
FS (%) 32.55±1.63 35.18±2.13 0.010 
Diastolic parameter    
E/E' 6.27±0.87 6.31±0.76 0.84 
Global ventricular performance    
MPI 0.28±0.01 0.33±0.04 0.003 
Cardiac morphological parameters    
LVEDD (cm) 3.42±0.45 3.12±0.30 0.006 
LVESD (cm) 2.06±0.17 2.05±0.39 0.380 
a Ejection fraction; b Fractional shortening; c Ratio of early filling velocity to early diastolic mitral annulus velocity; d myocardial performance index; e left 
ventricular end-diastolic diameter; f left ventricular end-systolic diameter 
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Discussion 
To our knowledge, this is the first study in Iran that 
investigated the effects of levothyroxine on cardiac function 
in children with subclinical hypothyroidism using systolic, 
diastolic and morphologic parameters. As observed, systolic 
parameters improved after treatment. In addition, treatment 
with levothyroxine had positive effects on MPI and LVEDD. 
So far, limited data has been published similar to our 
topic. In one study by Çatlı et al. (27) in Turkey, which was 
performed on 31 children with subclinical hypothyroidism, it 
was seen that the morphological parameters of LVEDD and 
LVESD increased in 6 months of treatment that the first 
result was in agreement with our finding, but the latter was 
not compatible with our data. Çatlı  et al. (27) also 
mentioned that other cardiac functional parameters, such as 
EF, FS and MPI did not significantly change after 6 months, 
which were contrary to our results. The authors stated that 
short duration of treatment might be a reason for lack of 
changes. The incompatibility between their results and ours 
might be due to differences in age, BMI, and/or serum levels 
of TSH and T4. Adult studies did not only showe that 
patients with subclinical hypothyroidism had impaired 
myocardial contractility and diastolic dysfunction, but also 
stated that these problems may be reversed with 
levothyroxine treatment (28-31). The study by Nakova et al. 
(10) on 54 patients showed that a 5-month levothyroxine 
treatment could contribute to higher EF and lower E/E'. 
Another research by Tadic et al. (32) on 54 Serbian women 
with subclinical hypothyroidism indicated that parameter of 
E/E' improved after 1-year treatment, but no changes were 
found in LVEDD and LVESD. The last results were 
compatible with the article by Ilic et al. (33), in which they 
reported that no significant changes were seen in LVEDD 
and LVESD after 1-year treatment with levothyroxine. A 
large-scale cohort study by Andersen et al. (34) revealed that 
levothyroxine treatment did not reduce risk of mortality in 
patients with subclinical hypothyroidism and heart disease. 
These data are helpful for clinicians to select a preventive 
and therapeutic approach against cardiac complications of 
subclinical hypothyroidism through levothyroxine  
administration, however, stronger evidence is needed in this 
regard. We also evaluated the effect of levothyroxine by sex. 
The notable point found from the results was improvement 
of E/E' parameter in boys but not in girls after treatment. 
This may be explained by differences in hormonal profiles 
between sexes. To the best of our knowledge, except Çatlı et 
al.' study, there are no other children studies to compare our 
findings with. Considering that the frequency of children 
with subclinical hypothyroidism is not low and they impose 
high economic costs on families and societies, addition of 
cardiac compactions following subclinical hypothyroidism 
increase pressure on children and their family. Therefore, 
more studies are suggested to be performed on children and 
adolescent patients with subclinical hypothyroidism. These 
studies can increase awareness and information about 
therapeutic drugs and help clinicians for better management 
of the patients. 
In most of the papers, it has been exhibited that 
subclinical hypothyroidism is related to different cardiac 
functional parameters (35, 36). Studies on patients with 
subclinical hypothyroidism, who underwent levothyroxine 
treatment, showed evidence of improving left ventricular 
systolic function. Therefore, subclinical hypothyroidism can 
be considered as a mild hypothyroidism which is associated 
with primary cardiovascular symptoms. Thus, starting early 
and timely treatment in these patients seems necessary to 
prevent cardiac involvement. 
One of the limitations of our study was the small sample 
size and relatively short follow-up period of study 
participants. Second, our study did not have an untreated 
control group (e.g., including patients who did not agree to 
undergo levothyroxine treatment) and we cannot certainly 
and strongly say that the observed improvements of cardiac 
function were a result of the levothyroxine treatment and not 
other factors, like physiological growth. Overall, it has been 
proposed to design new studies with bigger sample size, 
longer follow-up period and an untreated control group, plus 
assess other cardiac functional indices, such as left ventricle 
mass index, thickness of the left ventricle posterior wall, and 
mitral deceleration time. 
In conclusion, according to the results, it can be 
concluded that treatment with levothyroxine may improve 
cardiac functional parameters in the children with subclinical 
hypothyroidism. However, it is necessary to perform new 
studies with an untreated control group to confirm the 
positive effect of levothyroxine on cardiac functions in 
childhood subclinical hypothyroidism. 
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